
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Szafrański S, Joshi A, Steglich M, Yang I, Qu T, Behrens W, Muthukumarasamy U, Melidis D, Schaefer-Dreyer P, Grischke J, Hegermann J, Nejdl W, Häussler S, Stiesch M
Stankov M, Bruhn M, Hoffmann M, Salam A, Eichmann A, Nehlmeier I, Manthey L, Witte T, Pöhlmann S, Ahrenstorf G, Happle C, Dopfer-Jablonka A, Kalinke U, Behrens G
Sidarous L, Ibrahim M, Elhadidy M, Abouelfetouh A, Saif N, Aboelnaga N, Shehat M, Youssef M, Badr E
Immunomodulatory drugs for rheumatic diseases specifically influence immune cells and messenger substances. This project investigates their effect on immune responses in order to find individually suitable therapies.
This project focuses on lung infections such as influenza, COVID-19, pneumonia and tuberculosis in order to improve diagnostics, patient stratification and therapy. RNA molecules and metabolites are being investigated as biomarkers and complementary therapies.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
Ralf Meister, Bishop of the Evangelical-Lutheran Church of Hanover
“Participation and Resilience at the Interface between Science and Society”
Moritz Gaidt, IMP - Research Institute of Molecular Pathology, Vienna
Marylyn M. Addo - UKE Hamburg

